Imunon shares surge 11.14% premarket amid R&D day highlights on Phase 3 ovarian cancer trial progress and innovation.

Imunon (IMNN) surged 11.14% in premarket trading following the announcement of its upcoming R&D Day, which highlights clinical progress in its Phase 3 OVATION 3 trial for IMNN-001, a potential first-line immunotherapy for advanced ovarian cancer. Recent news underscores translational data demonstrating a 13-month overall survival extension and tumor microenvironment shifts, reinforcing the therapy’s potential. The company also confirmed a webcast to discuss innovation in ovarian cancer treatment, aligning with its focus on redefining care standards. These developments, coupled with prior positive trial updates and conference presentations, likely fueled investor optimism ahead of the Q3 2025 earnings release scheduled for the same day.